Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05965427
Other study ID # 606
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 1, 2023
Est. completion date December 2024

Study information

Verified date May 2024
Source NEAT ID Foundation
Contact Debbie Roberts, PhD
Phone 07956761151
Email debbie.roberts@rokcservices.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This data collection study aims to describe and compare the outcomes of Mpox on people living with HIV (PLHIV) and HIV-negative individuals who are on pre-exposure prophylaxis (PrEP). The study also aims to identify risk factors for specific Mpox outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of MPX was more than 90 days prior to data collection - Confirmed MPX infection by documented PCR testing of lesions between 1st May 2022 to 1st December 2023 - At least 18 years of age - Cases (PLWHIV + MPX) i) Documented HIV-1 infection - Cases (PrEP users + MPX) i) Attended a clinic to receive PrEP Exclusion Criteria: - MPX diagnosed based on clinical criteria only - MPX diagnosis was within the last 90 days

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No intervention
Study is retrospective data collection only

Locations

Country Name City State
France Hôpital Bichat Claude Bernard Paris
France Hôpital Pitié-Salpêtrière Paris
Poland Euroguidelines Warsaw
Spain Hospital Universitari Vall d'Hebron Barcelona
United Kingdom Chelsea and Westminster Hospital London

Sponsors (4)

Lead Sponsor Collaborator
NEAT ID Foundation European Commission, PENTA Foundation, VERDI Consortium

Countries where clinical trial is conducted

France,  Poland,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Severity of Mpox lesions Severity of lesions will be assessed by the peak number of lesions and peak number of sites.
Skin lesion at peak severity score:
Not presenting with skin lesions (0 skin lesions)
Mild (<25 lesions)
Moderate (25-99 skin lesions)
Severe (100-250 skin lesions)
Very severe (>250 skin lesions)
Site of lesion will also be collected as part of the severity assessment:
Genital lesions (defined as involvement of either vulva or vaginal mucosa or penis, pubic area)
Ano-rectal/perianal lesions
Oral mucosa (lips/gums/oral/pharynx) lesions
Face
Trunk (chest/torso/abdomen/back)
Limbs (arms/forearms/legs/hands/feet) on the body.
From date of disease onset (first symptom) until date of peak number of lesions and sites recorded (up to 3 months)
Primary Clinical complications associated with Mpox Complications which will be collected are as follows:
Severe rectal and/or perianal pain (i.e. due to perianal/anal abscess, proctitis)
Tonsillitis and/or dysphagia
Secondary bacterial infection on affected skin
Urological complications (genital oedema, urinary retention)
Ocular involvement (conjunctivitis, corneal involvement, periorbital cellulitis)
Central nervous system involvement (encephalitis, meningitis, focal neurology signs)
Pneumonia/pulmonary abscess or necrotizing involvement
Myocarditis
Diarrhoea
The definition of a mental health condition will be that reported by the patient and recognized in the ICD-10 classification.
From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death(up to 3 months)
Primary Percentage of hospitalisations percentage of hospitalisations for clinical reasons only (i.e. not for precautionary measures or quarantine). 1st May 2022 to 1st December 2023
Primary Death From date of disease onset (first symptom) until date of death related to Mpox (up to 3 months)
Primary Differences in the clinical manifestation of MPX in PLWHIV and PrEP users Clinical manifestations will include: Severity and time to resolution of lesions, severity of disease, clinical complications, drug treatments, length of hospitalisations, and number of deaths.
severe disease is defined as:
Adults with severe clinical illness (e.g. National Early Warning Score [NEWS] 2 score of =5), which may include significant lower respiratory symptoms, confusion/encephalitis, and other complications (e.g. secondary bacterial infection, sepsis)
Widely disseminated lesions and very many in number (=100)
Suspected infection of the cornea
Severe, refractory pain from lesions requiring hospitalisation to achieve symptomatic control
Lesions associated with complications due to pain or swelling (e.g., constipation, urinary retention, inability to swallow)
Confirmed infection, regardless of severity, in immunocompromised people, pregnant women, or children aged =16 years.
From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death(up to 3 months)
Primary Differences in the clinical manifestation of MPX in PLWHIV by CD4 and VL. Clinical manifestations will include: Severity and time to resolution of lesions, severity of disease, clinical complications, drug treatments, length of hospitalisations, and number of deaths.
severe disease is defined as:
Adults with severe clinical illness (e.g. National Early Warning Score [NEWS] 2 score of =5), which may include significant lower respiratory symptoms, confusion/encephalitis, and other complications (e.g. secondary bacterial infection, sepsis)
Widely disseminated lesions and very many in number (=100)
Suspected infection of the cornea
Severe, refractory pain from lesions requiring hospitalisation to achieve symptomatic control
Lesions associated with complications due to pain or swelling (e.g., constipation, urinary retention, inability to swallow)
Confirmed infection, regardless of severity, in immunocompromised people, pregnant women, or children aged =16 years.
From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death(up to 3 months)
Secondary Number of MPX patients attending as a percentage of total number of patients the sites have seen over a set period of time (from first Mpox patient to last Mpox patient) 1st May 2022 to 1st December 2023
Secondary Length of stay in hospital for inpatients treated for Mpox From date of hospital admission for Mpox until date of hospital discharge (up to 3 months)
Secondary Time to lesion resolution (if known) From date of disease onset (first symptom) until date of lesion resolution (up to 3 months)
Secondary Differences in the clinical manifestation of MPX in PLWHIV and PrEP users by co-morbidities. Clinical manifestations will include: Severity and time to resolution of lesions, severity of disease, clinical complications, drug treatments, length of hospitalisations, and number of deaths.
severe disease is defined as:
Adults with severe clinical illness (e.g. National Early Warning Score [NEWS] 2 score of =5), which may include significant lower respiratory symptoms, confusion/encephalitis, and other complications (e.g. secondary bacterial infection, sepsis)
Widely disseminated lesions and very many in number (=100)
Suspected infection of the cornea
Severe, refractory pain from lesions requiring hospitalisation to achieve symptomatic control
Lesions associated with complications due to pain or swelling (e.g., constipation, urinary retention, inability to swallow)
Confirmed infection, regardless of severity, in immunocompromised people, pregnant women, or children aged =16 years.
From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death(up to 3 months)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05512949 - Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine Phase 2
Completed NCT05976100 - Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years Phase 1
Recruiting NCT05988203 - A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines Phase 1
Terminated NCT05567939 - Clinical, Virological, Immunological, Psychosocial and Epidemiological Consequences of Human Monkeypox Virus (ProMPX)
Active, not recruiting NCT05562323 - Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study
Recruiting NCT05534984 - Study of Tecovirimat for Human Monkeypox Virus Phase 3
Not yet recruiting NCT05784038 - Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)
Not yet recruiting NCT05745987 - Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT Phase 4
Recruiting NCT05879965 - Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk
Completed NCT03745131 - Cohort Study of Healthcare Workers Receiving Imvanex®
Recruiting NCT05559099 - Tecovirimat for Treatment of Monkeypox Virus Phase 2
Completed NCT05846243 - Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years Phase 2/Phase 3
Not yet recruiting NCT05629299 - Pilot Study to Detect Monkey Pox Virus in Sperm: POXSPERM N/A
Recruiting NCT05654883 - New York City Observational Study of Mpox Immunity
Completed NCT05762523 - Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years Phase 1
Recruiting NCT05597735 - Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease Phase 3
Recruiting NCT05734508 - Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC Phase 4
Active, not recruiting NCT05740982 - A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox Phase 2
Recruiting NCT05947786 - Mpox Paediatric and Adolescent Clinical Study
Recruiting NCT06045923 - Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV